Aardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) saw a large increase in short interest in October. As of October 30th, there was short interest totaling 1,038,938 shares, an increase of 87.8% from the October 15th total of 553,262 shares. Approximately 5.8% of the company’s stock are sold short. Based on an average daily trading volume, of 2,760,064 shares, the days-to-cover ratio is currently 0.4 days.
Insider Transactions at Aardvark Therapeutics
In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00. Following the sale, the insider directly owned 35,475 shares in the company, valued at $183,760.50. This represents a 63.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 17.80% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Aardvark Therapeutics
Several institutional investors have recently added to or reduced their stakes in AARD. Bank of New York Mellon Corp boosted its holdings in Aardvark Therapeutics by 30.8% in the first quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock valued at $111,000 after purchasing an additional 6,905 shares in the last quarter. Empowered Funds LLC acquired a new stake in Aardvark Therapeutics during the third quarter worth approximately $124,000. Susquehanna International Group LLP acquired a new stake in Aardvark Therapeutics during the second quarter worth approximately $138,000. Ieq Capital LLC purchased a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth approximately $221,000. Finally, J. Goldman & Co LP purchased a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth approximately $233,000.
Aardvark Therapeutics Trading Down 12.5%
NASDAQ:AARD traded down $0.19 during trading hours on Friday, hitting $1.33. The company’s stock had a trading volume of 402,447 shares, compared to its average volume of 1,698,199. Aardvark Therapeutics has a 52-week low of $0.93 and a 52-week high of $16.60. The stock has a market capitalization of $29.10 million, a P/E ratio of -0.41 and a beta of 4.38. The stock has a fifty day moving average of $3.76 and a 200-day moving average of $5.72.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.19). On average, sell-side analysts forecast that Aardvark Therapeutics will post -3.05 earnings per share for the current year.
Wall Street Analysts Forecast Growth
AARD has been the topic of a number of recent research reports. Oppenheimer lowered Aardvark Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 26th. BTIG Research dropped coverage on Aardvark Therapeutics in a report on Monday, October 12th. They issued a “neutral” rating for the company. UBS Group set a $4.00 target price on Aardvark Therapeutics in a research note on Monday, October 19th. Raymond James Financial restated a “market perform” rating on shares of Aardvark Therapeutics in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Tuesday, September 29th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Aardvark Therapeutics presently has a consensus rating of “Hold” and an average target price of $11.56.
Check Out Our Latest Analysis on Aardvark Therapeutics
About Aardvark Therapeutics
Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.
Featured Stories
- Five stocks we like better than Aardvark Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
